Sigilon's Afibromer technology will be used to encapsulate insulin-producing cells for the potential treatment of type 1 diabetes
Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that its Afibromer™ Living Therapeutic candidate SIG-003 has been granted an Advanced Therapy Medicinal Product (ATMP) designation by the Committee for Advanced Therapies of the European Medicines Agency.
CAMBRIDGE, Mass., March 9, 2018 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that the company will present at Cowen & Company 38th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 8, 2018 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that the company will present at the following upcoming conferences.
Elsevier, the global information analytics business specializing in science and health, today announced that six start-up companies have been selected from more than 150 global applicants for The Hive, Elsevier’s innovation initiative for biotech and pharmaceutical start-ups......Sigilon Therapeutics.
Dr. Moller brings a long history of experience in drug discovery and development to the company, including a focus on development of therapeutics for metabolic disorders and in the identification and evaluation of emerging technologies.
Sigilon Therapeutics will present at the following conferences in January: Biotech Showcase 2018 and Cell & Gene Therapy World 2018.
Sigilon Therapeutics, today announced that it will host a live, online educational webinar “Beyond Gene Therapies: The Next Wave of Protein-Generating Therapeutics” on Monday, Dec. 4, 2017, at 10 a.m. EST. Following presentations by Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Sigilon scientific advisory board, journalist Luke Timmerman will moderate a discussion of questions submitted by audience participants on current methods and promising new protein delivery technologies.
Devyn Smith, Ph.D., Sigilon Therapeutics Chief Strategy Officer and Head of Operations, will present at the upcoming 2017 Biotech and Money Inv€$tival Showcase, organized in partnership with Jefferies LLC, and attend the Jefferies 2017 London Healthcare Conference taking place Nov. 15-16, 2017
“Mr. Shaff’s experience in company building, finance, and corporate development, notably in emerging areas of biotechnology, will be particularly helpful as we develop a new Afibromer™ cell factory approach to the treatment of chronic diseases,” said Douglas Cole, M.D., Chairman of the Board of Sigilon Therapeutics.
Follow our mission at Sigilon Therapeutics by opting in for important news and events.
In patients who suffer from Type I diabetes, pancreatic beta cells are killed off by the immune system. Lilly and Sigilon plan to encapsulate induced pluripotent stem cells that are engineered into insulin-producing pancreatic beta cells. Ultimately, the companies hope, these products can restore a person’s insulin production without alarming their immune system.
Sigilon Therapeutics Inc. (Cambridge, Mass.) granted Eli Lilly and Co. (NYSE:LLY) exclusive, worldwide rights to Sigilon’sType I diabetes program in a deal potentially worth over $470 million.
The startup is developing what it calls “living therapeutics” — drugs based on engineered cells that can fight a range of disorders when implanted in the body.
Today Sigilon is announcing a $473 million pact with Eli Lilly — which is stepping out under a bolder R&D chief in Dan Skovronsky — to drive their stem cell work on Type 1 diabetes into the clinic, with $63 million of that in an upfront and the rest divvied up with a goal of fully funding the development of a durable new therapy for the disease.
Medgadget editor Tom Peach recently spoke with Devyn Smith PhD, Chief Strategy Officer of Sigilon Therapeutics, to learn more about the company’s technology.
“Biotechs are surrounded by innovation; they make science fiction—a digital pill, 3D printing, wearable technology—a reality; are located in trendy tech hubs like San Francisco, San Diego, and Boston; and most importantly, they offer hope.”
A few months ago, Flagship unveiled Sigilon Therapeutics, a Cambridge startup that is aiming to develop a new class of “living therapeutics”
Four early-stage venture-funded biotechnology companies have signed leases at 100 Binney St. in Cambridge.
Sigilon Therapeutics’ discovery platform combines cell engineering and revolutionary biocompatible Afibromer™ technology, a new class of implantable biomaterials that do not trigger fibrosis.
Sigilon’s allogeneic cell therapy implants offer long-term but flexible dosing
Follow our mission at Sigilon Therapeutics by opting in for important news and events.
We are proud to be invited to speak at conferences about our technology. Below are some of the conferences where you can see and learn more about us:
Follow our mission at Sigilon Therapeutics by opting in for important news and events.
Peer-reviewed publications describing Sigilon Therapeutics’s research include:
Afibromer™ protein factories represent a flexible and programmable alternative to gene therapies.
When encapsulated with alginate derivatives that resist the foreign-body response, human embryonic stem cell–derived beta cells restore long-term normoglycemia in immunocompetent mice without the need for immunosuppression.
Implanted spheres of a broad variety of material classes significantly abrogate foreign body reactions and fibrosis in rodent and non-human primates when the spheres are larger than 1.5 mm in diameter.
In vivo screening of a large combinatorial library of alginates identifies materials that elicit a substantially reduced foreign body response.
Host recognition and immune-mediated foreign body response to biomaterials can compromise the performance of implanted medical devices.
Follow our mission at Sigilon Therapeutics by opting in for important news and events.
A 
Company
